Carl Zeiss Meditec: Tariff Refunds Can't Hide China's Refractive Slump
Third-quarter results show a company leaning on one-off tariff credits and a fresh restructuring push even as its core Chinese refractive engine sputters.
AFX.DE · Earnings Call · 2026-08-05
A Quarter That Distilled Two Forces
The nine-month scorecard Carl Zeiss Meditec delivered on August 5 is a study in contrasts. Revenue of €1.554 billion fell 2.2% year-over-year (FX-adjusted −0.7%), with adjusted EBITA margin slipping to 8.0% from 11.1% — yet the company quickly pivoted to a handful of forward-looking moves: a new Head of Ophthalmology, an order for 25 VISUMAX 800 lasers from Aier Group, and the first concrete ProfitUp restructuring decisions. The market’s takeaway seems to be that tariff refund temporarily cushions the blow, but the underlying business is still wrestling with a soft China refractive cycle and a delayed VBP process.
CFO Justus Wehmer was blunt about the current trajectory:
We know that in June, we were 8% below prior year and 5% in July below prior year.
That admission hits the company’s most profitable consumable line. Year-to-date procedure volumes in China were still slightly positive (roughly 2–3%), but the momentum is clearly melting. The summer peak, historically the biggest driver of treatment pack revenue, has started weakly, and management is now guiding toward the lower end of its own EBITA margin range of 8–10% for the full year.
Where the Pinch Is Sharpest
The IOL business remains the largest single drag. The recall of bifocal IOLs in China at the start of the fiscal year, followed by a postponement of the next volume-based tender (VBP), has created an extended gap. The successor lens has received license but can’t be sold until it is relisted under the new tender, now expected around December. As Wehmer noted, “there will be more Chinese contenders and also in the premium segment. So therefore, we would expect at least, I'd say, evenly harsh impact than what we have seen in the first round.” — Justus Wehmer, CFO · 2026-08-05 This is a starker tone than in prior quarters, when the company argued it could defend pricing and premium positioning.
Interestingly, the same call also offered an offsetting positive: a one-time tariff refund of €20.8 million, the bulk of which was recognized in the quarter. This refund is a company-unique expression of a broader global theme — this quarter’s global keyword list features IEEPA refund and tariff-related terms prominently. But the CFO was careful to note that the FY ’24/’25 portion is excluded from adjusted EBITA, so the net impact on guidance is neutral.
Strategic Moves Beyond the Numbers
The more forward-looking narrative came from the CEO, Andreas Pecher, who announced a strategic partnership with Aier Group for 25 VISUMAX 800 lasers. “Together with Aier Group, we will explore deeper collaborative innovation in areas such as international expansion, integrated digital workflows and platforms and AI-assisted diagnosis.” — Andreas Pecher, CEO · 2026-08-05 This is a meaningful vote of confidence in the refractive franchise at a time when procedure growth is stalling, and it signals that the company still sees high untapped potential in China despite the near-term weakness.
Equally notable is the ProfitUp program’s first concrete actions — closing the Westerburg handpiece site, shifting production to Chesterfield, and planning a new manufacturing hub in India. The company also announced it will sunset the QUATERA platform and wind down the Katalyst portfolio. These are structural changes that go beyond typical quarterly cost cutting. As the CFO explained, “we are consolidating handpiece production by closing the door site in Westerburg, Germany and shifting all handpiece production to Chesterfield, U.S., allowing us to improve scale and operational efficiency.” — Justus Wehmer, CFO · 2026-08-05 The savings are expected to be back-end loaded, with minimal impact next fiscal year but more meaningful contribution toward the €160 million target.
Elasticity of the Summer Peak
The company’s own keyword trajectory shows how central the summer peak has become to the story. In prior quarters (20262, 20261, 20243), management repeatedly expressed cautious optimism about a rebound. Today’s language is more measured. The CFO acknowledged the pattern has shifted: “I think for the eight years that I'm here, Q1 has always been the softest quarter. And I would basically expect that to be fairly similar. The question is how deep is the trough?” — Justus Wehmer, CFO · 2026-08-05 That is a meaningful shift from the more hopeful tone in the December call, where he described the order book and product cycle as providing tailwinds.
The contrast with the prior quarter is instructive. In the May 2026 call, the same CFO said, “We have clearly baked in some caution on the refractive margin development into that perspective.” — Justus Wehmer, Management (likely CEO or senior executive) · 2026-05-13 That caution now looks prescient; the company has been forced to reinforce it with actual restructuring decisions.
Tariff Refund: A Welcome but Temporary Cushion
The tariff refund is arguably the most distinctive keyword for this quarter — it didn’t appear in any of the prior 12 company quarters. It reflects a broader global theme, but for this company it is a one-time accounting benefit tied to U.S. tariffs paid in previous years. The order entry decline of 5.5% and backlog stability suggest underlying demand is still soft, so the refund should be viewed as smoothing rather than solving.
Meanwhile, the VBP process and the IOL recall continue to weigh on the ophthalmology division, which runs at a 5.2% EBITA margin versus 11.1% a year earlier. The goodwill impairment of ~€150M expected in Q4 is a non-cash acknowledgment that the IanTECH acquisition has not delivered the expected value.
Bottom Line
This is a company in transition: it is simultaneously trying to defend a core franchise in China, execute a large restructuring, and introduce new products (TORUS, new IOLs) to revive growth. The tariff refund and the Aier deal offer bright spots, but the near-term guidance — revenue between €2.15B and €2.20B and EBITA margin at the lower end of 8–10% — suggests the market will need patience. The stock’s drawdown from peak (over 40% in the last two years) already reflects many of these challenges; the question now is whether the ProfitUp program and new product cycle can provide a floor.